TCE2.F Celldex Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
25.38 EUR
Close of Nov 13, 2026
18.90 38.34
Market cap
EUR 1.99B
P/E
-
P/B
3.66x
ROE
-46.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is TCE2.F undervalued?

Graham number

The Graham number of Celldex Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Celldex Therapeutics Inc fundamental analysis

No fundamental analysis for Celldex Therapeutics Inc yet.

Celldex Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT recep…

Full company profile